Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CYP3A4*3 allele: is it really rare?
van Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J. van Schaik RH, et al. Among authors: van fessem m, van den anker jn. Clin Chem. 2001 Jun;47(6):1104-6. Clin Chem. 2001. PMID: 11375299 No abstract available.
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T. Hesselink DA, et al. Among authors: van der werf m, van gelder t, van schaik rh, van der heiden ip. Clin Pharmacol Ther. 2003 Sep;74(3):245-54. doi: 10.1016/S0009-9236(03)00168-1. Clin Pharmacol Ther. 2003. PMID: 12966368
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.
Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA. Hesselink DA, et al. Among authors: van dam t, van gelder t, van der werf m, van schaik rh, van der heiden ip. Clin Pharmacol Ther. 2004 Dec;76(6):545-56. doi: 10.1016/j.clpt.2004.08.022. Clin Pharmacol Ther. 2004. PMID: 15592326
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Pisarski P, Le Meur Y, Mamelok RD, van Gelder T. Hesselink DA, et al. Among authors: van agteren m, van gelder t, van schaik rh. Pharmacogenet Genomics. 2008 Apr;18(4):339-48. doi: 10.1097/FPC.0b013e3282f75f88. Pharmacogenet Genomics. 2008. PMID: 18334918 Clinical Trial.
424 results